An observational study in Hypertension and Dyslipidemias, sponsored by Daewoong Pharmaceutical Co. LTD.. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.
In this study, investigator will evaluate subjects' clinical performance in actual care. Laboratory test results such as demographic information and medical treatment, blood pressure, blood lipid test, and liver function test conducted at the start date of Olomax tablet administration and subsequent 24 weeks (± 8 weeks) will be collected. In the case of safety-related information, such as abnormal cases, data shall be collected at any time during the 24-week follow-up period if there is a visit by the study subject according to daily treatment.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 4,000 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study is to confirm the effect of olomax tablet -reducing blood pressure and LDL-C- in patients with hypertension and dyslipidemia compared to existing drugs . Of the total 4,672,648 statin prescriptions in 2020, about 295,379 were combined prescriptions for hypertension treatment. It was expected that about 1% of them could be registered, and therefore we estimated 4,000 study subjects to be recruited.
A patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement.
Exclusion Criteria:
received olomax tablet as treatment.
Drug: Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
The rate of change in LDL-C
The rate of change in LDL-C at 12 weeks from baseline
Time frame: at 24 weeks
The amount of change in LDL-C
The amount of change in LDL-C at 24 weeks from baseline
Time frame: at 24 weeks
The rate of change in LDL-C
The rate of change in LDL-C at 12 weeks from baseline
Time frame: at 12 weeks
The amount of change in LDL-C
The amount of change in LDL-C at 12 weeks from baseline
Time frame: at 12 weeks
The rate of change in SBP(Systolic Blood Pressure)
The rate of change in SBP(Systolic Blood Pressure) at 12 weeks from baseline
Time frame: 12 weeks
The rate of change in SBP(Systolic Blood Pressure)
The rate of change in SBP(Systolic Blood Pressure) at 24 weeks from baseline
Time frame: 24 weeks
The amount of change in SBP(Systolic Blood Pressure)
The amount of change in SBP(Systolic Blood Pressure) at 12 weeks from baseline
Time frame: 12 weeks
The amount of change in SBP(Systolic Blood Pressure)
The amount of change in SBP(Systolic Blood Pressure) at 24 weeks from baseline
Time frame: 24 weeks
The rate of change in lipid variable(TC, HDL-C, non-HDL-C, TG)
The rate of change in lipid variable(TC, HDL-C, non-HDL-C, TG) at 12 weeks from baseline
Time frame: 12 weeks
The rate of change in lipid variable(TC, HDL-C, non-HDL-C, TG)
The rate of change in lipid variable(TC, HDL-C, non-HDL-C, TG) at 24 weeks from baseline
Time frame: 24 weeks
The amount of change in lipid variable(TC, HDL-C, non-HDL-C, TG)
The amount of change in lipid variable(TC, HDL-C, non-HDL-C, TG) at 12 weeks from baseline
Time frame: 12 weeks
The amount of change in lipid variable(TC, HDL-C, non-HDL-C, TG)
The amount of change in lipid variable(TC, HDL-C, non-HDL-C, TG) at 24 weeks from baseline
Time frame: 24 weeks
Percentage of subjects who reached LDL-C target
Percentage of subjects who reached LDL-C target according to Korean Society of Lipid/Arteriosclerosis's risk classification in the guidelines for the treatment of dyslipidemia (2018) at 12 weeks from baseline
Time frame: 12 weeks
Percentage of subjects who reached LDL-C target
Percentage of subjects who reached LDL-C target according to Korean Society of Lipid/Arteriosclerosis's risk classification in the guidelines for the treatment of dyslipidemia (2018) at 24 weeks from baseline
Time frame: 24 weeks
Plan to share: Undecided — Do not have plan yet
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.